Positive early data supports Telix's pipeline differentiation; monitor full efficacy results from OPTIMAL-PSMA and regulatory milestones for TLX597-Tx and TLX591-Tx (Phase 3 ProstACT Global).
TLX drugs
TLX drug pipeline →- ◆ ITM-11 4/10 Phase 3 (completed)
- ● TLX591-Tx 4/10 Phase 3
- ● Zircaix 4/10 Phase 3 (ZIRCON) completed; BLA under FDA review
- ▲ Gozellix 3/10 Approved (FDA, March 21, 2025 — NDA 219592, 505(b)(2))
- ● TLX101-Tx 3/10 Phase 3 (pivotal, just initiated); Phase 1 safety stage complete
- All TLX drugs, catalysts & trials →
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 30 $11.00entry
- T+1 · 7mo ago +2.36%α +2.14% · $11.26
- T+5 · 6mo ago −3.09%α −4.82% · $10.66
- T+20 · 6mo ago −14.27%α −19.50% · $9.43
- T+60 · 4mo ago −9.27%α −12.38% · $9.98
Price Chart
How similar events traded
Executive Summary
Telix announces positive dosimetry data from Phase 2 OPTIMAL-PSMA trial of TLX597-Tx in mCRPC, showing low salivary gland and kidney uptake enabling dose intensification. The company is initiating a Phase 2 study (OPTIMAL-E) in mHSPC, advancing its pipeline in earlier-stage prostate cancer.
Key Facts
- TLX597-Tx dosimetry demonstrates reduced radiation to salivary glands and kidneys compared to existing PSMA RLTs.
- Dose-intensification regimen (8.5 GBq per cycle) shows potential for higher tumor uptake and wider therapeutic window.
- Phase 2 OPTIMAL-E trial initiated in metastatic hormone-sensitive prostate cancer (mHSPC).
- Data presented at 2026 International Prostate Cancer Symposium (IPCS 2026).
Financial Impact
No financial figures disclosed; potential depends on future clinical success and regulatory approval.
Risk Factors
- Clinical trial failure or safety issues in later stages.
- Competition from other PSMA-targeted therapies (e.g., Pluvicto).
- Regulatory approval uncertainty and commercialization challenges.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3284336 |
Track record
27 reports on TLX
9 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.
Filters
- Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
- Oct 20, 202627d ago 6-K Neutral 4/10 No price data
- Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
- Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
- Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
- Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
- Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers